Pulse Biosciences, Inc · NASDAQ:PLSE

Pulse Biosciences — Investor Presentation (April 2026)

14 slides from Pulse Biosciences's investor presentation, Apr 25, 2026

  1. Slide 1: Welcome to Pulse Biosciences Analyst & Investor Event

    Welcome to Pulse Biosciences Analyst & Investor Event Saturday, April 25 12:45 pm CT Event Start Prepared Remarks followed by Q&A ©2026 Pulse Biosciences, Inc. All rights reserved. 1

  2. Slide 2: Today's Speakers

    Today's Speakers: Speaker: Dr. David Kenigsberg Chief Medical Officer, Electrophysiology at Pulse Biosciences Presenting: Clinical Data and IDE Overview Medical Director of Cardiac Electrophysiology at HCA Westside Hospital Joining for Q&A: Paul LaViolette Darrin Uecker Chief Executive Officer Chief

  3. Slide 3: Nanosecond PFA System Characteristics

    Nanosecond PFA System Characteristics 12 sensing electrodes (10 on spline, 2 on Graphical User Interface nPulse shaft) Console 1 EM Sensor internal 22mm inner ring ablation electrode 30mm outer ring ablation electrode Epicenter Catheter ©2026 Pulse Biosciences, Inc. All rights reserved.

  4. Slide 4: nsPFA Catheter Pulmonary Vein Isolation Workflow

    nsPFA Catheter Pulmonary Vein Isolation Workflow Ostial PF Application • Two Applications per Pulmonary Vein • Single ostial application • Single antral application • Depending on Anatomy • Single anterior carina applications on each side Antral PF Application • Potential additional right-sided lesi

  5. Slide 5: nsPFA FIH Trial Study Overview

    nsPFA FIH Trial Study Overview Study Objective: • To assess initial safety (rate of acute adverse events within 30 days Total Cohort post-ablation) and effectiveness (acute procedural success at 6 and 12 N = 177 months) the Epicenter Catheter System. Study Population: • Adult patients who have faile

  6. Slide 6: nsPFA FIH Trial Patient Demographics

    nsPFA FIH Trial Patient Demographics Characteristic Total 5 Sec. Cohort Characteristic Total 5 Sec. Population Population Cohort (n=177) (n=141) (n=177) (n=141) Age, yr 60.6 ± 9.7 60.4 ± 9.9 Hypertension, % 56 56 Female, % 36% 37% Heart failure, % 2 2 BMI 28 28 Coronary Artery Disease, % 7 8 LV Ejec

  7. Slide 7: Procedure Time and %Success

    Procedure Time and %Success Characteristic Total Population 5 Sec. Cohort (n=177) (n=141) # of Subjects 177 141 Procedure Time, mins 61.1 ± 27.2 60.2 ± 27.7 LA Dwell Time, mins 19.4 ± 13.3 18.6 ± 13.0 Fluoroscopy Time, mins 8.7 ± 5.5 9.4 ± 5.9 # of PV applications / subject 12.6 ± 2.7 12.3 ± 2.6 Acu

  8. Slide 8: nsPFA FIH Trial Primary Safety Endpoint

    nsPFA FIH Trial Primary Safety Endpoint 5.0-Sec Total Population Cohort N=177 N=141 Asymptomatic Cerebral Embolism -- -- Atrio-esophageal Fistula -- -- Bleeding Requiring Transfusion -- -- Cardiac Perforation/Tamponade * 1 1 Death -- -- Esophageal Injury Resulting in Perforation -- -- Myocardial Inf

  9. Slide 9: nsPFA FIH Trial Freedom from AF/AFL/AT

    nsPFA FIH Trial Freedom from AF/AFL/AT Freedom from Atrial Arrhythmias by Cohort (5.0s vs 2.5s) 1-Yr Success 2.5-sec: 79.4% (95%CI 61.4 – 89.6%) 5-sec: 89.7% (95%CI 80.5 – 94.6%) Time after PFA (days) Follow-up: TTMs (weekly) & 24hr-Holters (6 & 12 M) ©2026 Pulse Biosciences, Inc. All rights reserve

  10. Slide 10: Data Summary

    Data Summary April 2026 Metric 5s Cohort PATIENT & PROCEDURE OVERVIEW # of Subjects 141 Procedure Time (mins) 60.2 ± 27.7 LA Dwell Time (mins) 18.6 ± 13.0 Fluoroscopy Time (mins) 9.4 ± 5.9 Avg # Applications 12.3 ± 2.6* 6M & 12M HOLTER MONITORING 6M Procedure Success by Holter, % 100% (95/95) 12M Pr

  11. Slide 11: nsPFA FIH Trial Conclusions

    nsPFA FIH Trial Conclusions • Nanosecond PFA is: – Efficient • Average No. of applications for PVI/pt = 12.3±2.6 • Left atrial dwell time = 18.6±13.0 min – Safe – Durable – Excellent clinical outcomes • Limitations: – Intermittent monitoring follow-up – Most cases performed with minimal EAM support

  12. Slide 12: NANOPULSE-AF IDE Pivotal Study

    NANOPULSE-AF IDE Pivotal Study Study Overview Target enrollment ~215 patients Clinical sites Up to 30 First patients enrolled 2Q26 Enrollment target FY 2026 Primary endpoints 6- and 12-months post- ablation procedural success and safety outcomes Status: initial patients treated – 7 in one day from a

  13. Slide 13: Next Gen nPulse Cardiac Catheter – Continuous Market Expansion

    Next Gen nPulse Cardiac Catheter – Continuous Market Expansion • Enables Single Catheter Workflow: building on the platform to enable Pulmonary Vein Isolation / Posterior Wall Isolation and Mitral Isthmus / Cavotricuspid Isthmus lines with switchable electrodes • Pre-clinical focal data presented in

  14. Slide 14: Questions

    Questions ©2025 Pulse Biosciences, Inc. All rights reserved. 14

Pulse Biosciences — Investor Presentation (April 2026) on 6ix